ReviewSelective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: A systematic review and meta-analysis
Introduction
Approximately 20% of all patients who experience a major depressive episode develop a chronic course (Gilmer et al., 2005) and approximately 47% of patients who are treated in mental health care facility suffer from some form of chronic depression (Torpey and Klein, 2008). Four subtypes of chronic depression are usually distinguished: (1) dysthymia, (2) chronic major depression, (3) recurrent major depression with incomplete remission between episodes, and (4) double depression (Klein, 2010). Dysthymic disorder is defined as a mild condition that is chronic and persistent for at least 2 years. A major depressive episode, chronic type, refers to a more severe condition that meets all criteria for major depression continuously for a minimum of 2 years. Patients who have recovered to the point where they no longer meet all criteria for a major depressive episode but continue to experience significant symptoms for a total duration of illness greater than 2 years are referred to as having recurrent major depression with incomplete remission during episodes. The superimposition of a major depressive episode on antecedent dysthymia is referred to as double depression (Klein, 2010).
Chronic depression is associated with increased functional impairment (Satyanarayana et al., 2009), increased health care utilization, and higher rates of hospitalization compared with non-chronic forms of depression (Berndt et al., 2000, Gilmer et al., 2005).
Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are two groups of antidepressants often used as pharmacological interventions in the treatment of chronic depression. An increasing number of studies have assessed the efficacy and effectiveness of these two groups of antidepressants in the last several decades.
These studies have been partly summarized in current guidelines and systematic reviews. Meta-analytic findings regarding the treatment of dysthymic patients showed that both types of antidepressants are effective but highlighted the differential acceptability of the two drug groups (Lima et al., 2005). Accordingly, the practice guideline for the treatment of patients with major depressive disorder of the American Psychiatric Association (American Psychiatric Association, 2010) comes to the conclusion, that both types of antidepressants are effective in the treatment of dysthymia and may also be used for other forms of chronic depression. The national clinical practice guideline for the treatment and management of depression in adults of the National Institute for Health and Clinical Excellence (National Institute for Health and Clinical Excellence (NICE), 2009) further highlights that SSRIs are better tolerated than TCAs by patients suffering from subthreshold depressive symptoms (including dysthymia). In contrast to these findings, the superiority of antidepressants to placebo was questioned for mild to moderately depressed patients in a controversially discussed meta-analysis (Kirsch et al., 2008). Thus, it remains unclear how chronicity and severity of depression influence the effectiveness of antidepressants. A systematic review considering the whole spectrum (i.e., all subtypes) of chronic depressions is still missing.
The objectives of this systematic review are first to examine the efficacy and acceptability of SSRIs and TCAs in the treatment of chronic depression, and second, to assess the comparative effectiveness of the two types of antidepressants.
Section snippets
Methods
The methods and results are reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Moher et al., 2009). Methods were specified a priori in a freely accessible review protocol, which included a detailed description of the methods, which are summarized briefly here (Kriston et al., 2010).
Study selection
After the removal of 1710 duplicates 2417 potentially relevant publications were identified through the electronic database search (Fig. 1). The number of publications was reduced to 275 after screening the title and abstract. Through the additional search strategies another 83 possibly relevant studies were identified. Of these 358 studies, seven studies were not available in full text. The full text of the available studies was screened and 20 primary studies, reported in 51 publications,
Summary
Similar results were obtained in terms of efficacy for both SSRIs and TCAs. Both classes of drugs showed statistically significant higher rates of response and remission than their placebo control treatments. The low NNTs assessed for both SSRIs and TCAs further highlight the clinical relevance of our findings, more precisely between four and seven patients have to be treated to cause one additional clinical improvement. No differences in terms of efficacy could be detected in studies directly
Conclusions
This systematic review provides evidence for the efficacy of SSRIs and TCAs in the treatment of chronic depression. As both groups of drugs lead to promising results, clinicians may make treatment decisions about the best option based upon the patients' personal needs and drug tolerance. As TCAs are more likely to produce dropouts and adverse events than SSRIs, SSRIs seem to be the first choice for the treatment of chronic depression. These findings may serve as supplementary information for
Role of funding source
This study was funded by a grant from the German Ministry of Education and Research (project 01KG0923).
Conflict of interest
All other authors declare that they have no conflicts of interest.
Acknowledgments
None.
References (42)
- et al.
Interleukin-1 beta production in dysthymia before and after pharmacotherapy
Biological Psychiatry
(1999) - et al.
Sertraline is more effective than imipramine in the treatment of non-melancholic depression: Results from a multicentre, randomized study
Progress in Neuro-Psychopharmacology and Biological Psychiatry
(2003) - et al.
Meta-analysis in clinical trials
Controlled Clinical Trials
(1986) - et al.
Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder
American Journal of Geriatric Psychiatry
(2005) - et al.
Lomg-term treatment of double depression - a preliminary-study with serotonergic antidepressants
Progress in Neuro-Psychopharmacology and Biological Psychiatry
(1994) - et al.
A preliminary study of serotonergic antidepressants in treatment of Dysthymia
Progress in Neuro-Psychopharmacology and Biological Psychiatry
(1992) - et al.
Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing Fluoxetine to Imipramine
Journal of Affective Disorders
(2006) - et al.
The Nottingham study of neurotic disorder: comparison of drug and psychological treatments
Lancet
(1988) - et al.
Role of selective serotonin reuptake inhibitors on the treatment of chronic and/or resistant major depression
Giornale Di Neuropsicofarmacologia
(1995) Practice Guideline for the Treatment of Patients with Major Depressive Disorder
(2010)
Ritanserin, imipramine and placebo in the treatment of dysthymic disorder
Journal of Clinical Psychopharmacology
Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years
Journal of Family Practice
Lost human capital from early-onset chronic depression
American Journal of Psychiatry
Atypical antipsychotic drugs in dysthymia: placebo controlled studies of amisulpride versus imipramine, versus amineptine
European Psychiatry
Systematic reviews in health care
Meta-Analysis in Context
Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project
Acta Psychiatrica Scandinavica
Ecitalopram versus placebo in the treatment of dysthymic disorder
International Clinical Psychopharmacology
A randomized double-blind study of fluoxetine versus placebo in the treatment of Dysthymia
American Journal of Psychiatry
Measuring inconsistency in meta-analyses
BMJ—British Medical Journal
The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine
Journal of Clinical Psychiatry
Cited by (87)
Bupropion monotherapy alters neurotrophic and inflammatory markers in patients of major depressive disorder
2021, Pharmacology Biochemistry and BehaviorCitation Excerpt :The above drugs primarily act by increasing the levels of monoamines (serotonin, norepinephrine, dopamine) in the central nervous system (CNS) through various mechanisms. However, antidepressant drugs are associated with a variety of adverse effects such as anticholinergic, cardiac, orthostatic hypotension, gastrointestinal, genitourinary effects, sexual dysfunctions, weight gain and serotonin syndrome (Carvalho et al., 2016; Papakostas, 2008; von Wolff et al., 2013). These adverse effects are a major contributor to treatment discontinuation and lack of patient compliance – with rates as high as 43% in first 3 months and 27% in the second 3 months of treatment initiation (Bull et al., 2002).
Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications
2020, The Lancet PsychiatryChallenges in psychosocial research in renal populations
2020, Psychosocial Aspects of Chronic Kidney Disease: Exploring the Impact of CKD, Dialysis, and Transplantation on PatientsDepression in patients with CKD and ESRD
2020, Psychosocial Aspects of Chronic Kidney Disease: Exploring the Impact of CKD, Dialysis, and Transplantation on Patients